Journal Article
Review
Add like
Add dislike
Add to saved papers

Postradiation cutaneous vascular tumors of the breast: a review.

Postradiation vascular tumors fall into two categories: (1) postradiation cutaneous angiosarcoma, malignant vascular neoplasms with significant morbidity and mortality; and (2) atypical vascular lesions (AVL), vascular tumors that reportedly behave in a benign manner. Postradiation vascular tumors not only present a therapeutic problem for clinicians, but they present an increasingly common diagnostic dilemma for pathologists. Although first described separately 15 years ago, the relationship between postradiation cutaneous angiosarcoma and AVL remains controversial. It appears that, in at least some cases, angiosarcoma can arise in the context of AVL, suggesting that these lesions are part of a spectrum of the same disease process. This latter view point is supported by the significant clinical and histologic overlap found between both tumors. Herein, we will discuss the evolution of this topic while reviewing the various clinical, histopathologic, and prognostic characteristics of postradiation cutaneous angiosarcoma and AVL.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app